KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin. PMID 42413960 · Clin Infect Dis · 2026-Jul-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial. PMID 42479626 · J Crohns Colitis · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem. PMID 42449715 · Cancers (Basel) · 2026-Jul-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study. PMID 42413781 · J Am Acad Dermatol · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Everolimus and de novo malignancies after liver transplantation: a Nationwide Emulated Trial Using Real-World Data. PMID 42413767 · JHEP Rep · 2026-Jul-07 The study is a non-randomized, observational analysis using an 'emulated target trial' framework. While it is oncological, involves humans, has a drug intervention, and reports time-to-event efficacy results, it fails the core requirement of being a randomized controlled trial and does not have an explicitly stated Phase III/IIIb or Phase II/III classification.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. PMID 42413526 · Lancet Respir Med · 2026-Jul-07 The record describes a single-arm, Phase 1b/2 trial with a primary endpoint of ORR. It is not a randomized Phase III/IIIb or Phase II/III trial and lacks a time-to-event efficacy endpoint.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC). PMID 42412689 · Future Oncol · 2026-Jul-07 The record describes a modeling and transportability analysis (a 'Targeted literature review' and 'Outcome regression models') using data from other trials (RATIONALE-315, RATIONALE-303, RATIONALE-312). It is not a primary, original result report of a Phase III randomized trial with a drug intervention and a time-to-event endpoint. The publication is a secondary analysis, likely a health-economic or modeling study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid. PMID 42333640 · J Am Heart Assoc · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen. PMID 42223961 · JAMA · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial. PMID 42153665 · Circulation · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intra-Arterial thrombolysis after SUCCESSful angiographic recanalization in acute large-vessel occlusion stroke of the anterior circulation (IA-SUCCESS): a multicentre, randomised, clinical trial protocol. PMID 42439416 · Eur Stroke J · 2026-Jul-06 方案论文未报告临床试验结果。
H L
旧查询独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of endoscopic screening for non-cardia gastric cancer: a 12-year report of a population-based randomized trial. PMID 42410417 · BMC Med · 2026-Jul-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Laparoscopic versus open pancreaticoduodenectomy for non-pancreatic periampullary adenocarcinomas: study protocol for a multicentre randomised controlled trial in China. PMID 42409398 · BMJ Open · 2026-Jul-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Locoregional recurrence patterns and prognostic outcomes in early-stage natural killer/T-cell lymphoma treated with sandwich chemoradiotherapy: A post hoc analysis of a randomized controlled trial. PMID 42409316 · Pract Radiat Oncol · 2026-Jul-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Multi-Center Randomized Trial Evaluating the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) for Vascular Occlusion of Hypervascular Tumors. PMID 42409306 · J Vasc Interv Radiol · 2026-Jul-06 The study is a randomized trial of a device (hydrogel embolic system) for tumor embolization. It does not involve a drug intervention and does not report a time-to-event efficacy endpoint; the primary endpoints are safety (Freedom from MAE) and technical success (effectiveness). It is therefore ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 study]. PMID 42409049 · Pneumologie · 2026-Jul-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial. PMID 42406777 · Hum Reprod · 2026-Jul-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study. PMID 42403263 · Diabetes Obes Metab · 2026-Jul-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-Centre, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental Fat. PMID 42401423 · Aesthet Surg J · 2026-Jul-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial. PMID 42401951 · BMC Pharmacol Toxicol · 2026-Jul-04 The study is an original, randomized, oncology trial with a drug intervention, but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, while a time-to-event measure (time-to-onset of neuropathy) is reported, it is a secondary endpoint related to toxicity, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) required for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preoperative whey protein supplementation for postoperative nausea, vomiting and recovery in well-nourished gynecologic tumor patients: a randomized controlled trial. PMID 42401710 · Sci Rep · 2026-Jul-04 The study is a randomized trial in gynecologic oncology patients (human, oncology). It is an original primary result report. However, it is excluded because: 1) the primary endpoint is incidence of postoperative nausea and vomiting (PONV), a binary outcome, not a time-to-event endpoint (OS, PFS, DFS, etc.) with KM/HR; 2) the intervention is a nutritional supplement (whey protein), not a systemic drug (chemotherapy, targeted therapy, immunotherapy, etc.); 3) the trial phase is not specified, and it does not appear to be a definitive Phase III/IIIb trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combined indwelling pleural catheter with thoracoscopic talc poudrage for malignant pleural effusion management: a randomized non-inferiority trial. PMID 42399890 · BMC Pulm Med · 2026-Jul-04 The study is a randomized trial in oncology (malignant pleural effusion) with original results, but it is not a Phase III/IIIb or Phase II/III trial (phase unclear from text, not explicitly stated as such), does not have a drug-containing intervention (comparing procedural techniques: IPC + TTP vs. TTP alone), and does not have a primary/key secondary time-to-event efficacy endpoint (primary endpoint is pleurodesis success rate at 12 weeks, a binary outcome, not time-to-event).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trial. PMID 42399751 · BMC Anesthesiol · 2026-Jul-04 The study is a randomized trial in breast cancer patients, but the intervention is a perioperative anesthetic regimen (opioid-free vs. opioid-based), not a systemic oncology drug treatment. The primary endpoint is a patient-reported anxiety score at 24 hours, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the criteria for a drug intervention or a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. PMID 42251856 · Lancet · 2026-Jul-04 The study is a randomized, phase 3 trial of a drug-containing intervention (CagriSema) in humans, with original results. However, it is not an oncology study; it evaluates a treatment for type 2 diabetes, a non-malignant condition. The primary efficacy endpoint is mean HbA1c change, which is a continuous measure, not a time-to-event outcome. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR. PMID 42398914 · Ophthalmol Retina · 2026-Jul-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. PMID 42398520 · Lancet Oncol · 2026-Jul-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study. PMID 42398333 · Vaccine · 2026-Jul-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A carotenoid-rich functional tomato sauce (OsteoCol®) reduces liver fat content in adults with metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial. PMID 42397564 · Eur J Nutr · 2026-Jul-03 The study is a randomized, placebo-controlled trial of a functional food (tomato sauce) for metabolic dysfunction-associated steatotic liver disease (MASLD), a non-oncologic condition. It does not involve a drug intervention, does not report a time-to-event efficacy endpoint (OS, PFS, etc.), and does not specify a Phase III/IIIb or Phase II/III trial design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials. PMID 42397072 · Br J Dermatol · 2026-Jul-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges? PMID 42396965 · Int Forum Allergy Rhinol · 2026-Jul-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study. PMID 42396885 · Headache · 2026-Jul-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study. PMID 42497096 · Age Ageing · 2026-Jul-02 The study is not an oncology trial. The primary endpoint is a composite healthspan outcome (cardiovascular disease, diabetes, dementia, cancer, or death) in a general older adult population for primary prevention, not a trial of a drug for the treatment of a specific human malignant neoplasm.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis. PMID 42393486 · BioDrugs · 2026-Jul-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management. PMID 42392242 · Crit Rev Oncol Hematol · 2026-Jul-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). PMID 42391581 · J Clin Oncol · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ablative radiotherapy in castration-resistant prostate cancer. PMID 42389925 · BJU Int · 2026-Jul-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a post-hoc analysis of the RIDTS trial. PMID 42389836 · Haematologica · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. PMID 42389818 · Haematologica · 2026-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy. PMID 42389794 · Circ Heart Fail · 2026-Jul-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. PMID 42384870 · N Engl J Med · 2026-Jul-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial. PMID 41812214 · Blood · 2026-Jul-02 The record meets most eligibility criteria but lacks explicit evidence of being a Phase III/IIIb or Phase II/III trial, which is a required criterion for inclusion. Metadata does not confirm the trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Secondary Analysis of a Randomized Clinical Trial. PMID 42507446 · JAMA Netw Open · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. PMID 42475098 · JAMA Netw Open · 2026-Jul-01 The trial is an original Phase III randomized study in human bladder cancer with time-to-event endpoints (OS, DFS). However, the intervention is a specialized oral nutrition formula (immunonutrition) and not a drug, which fails the required drug-intervention criterion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses. PMID 42456525 · Cancer Genet · 2026-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Treatment Satisfaction, Improvements in Jawline Definition, and Psychosocial Impact With OnabotulinumtoxinA for Platysma Prominence: Patient-Reported Outcomes From 2 Multicenter, Randomized, Placebo-Controlled Phase 3 Studies. PMID 42400884 · Aesthet Surg J · 2026-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy in Resectable Colon Cancer: Evidence, Controversies, and an Implementation Roadmap for 2026. PMID 42390664 · Ann Surg Oncol · 2026-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study. PMID 42387482 · BMC Med · 2026-Jul-01 The report is an original, randomized, oncology trial with a drug intervention and time-to-event endpoints, but it is a secondary analysis (renal injury) rather than the primary or key secondary efficacy analysis of the trial. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided information.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials. PMID 42387164 · Dermatol Ther (Heidelb) · 2026-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines. PMID 42386770 · NPJ Vaccines · 2026-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial. PMID 42386316 · BMJ · 2026-Jul-01 The trial is a Phase III randomized trial in oncology (pancreatic cancer) but does not meet the required criteria for a drug-containing intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The intervention is purely surgical, and the primary endpoint is a composite measure of postoperative functional recovery, not a Kaplan-Meier-analyzed survival or progression metric.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -